Immunotherapy extends survival in advanced bladder cancer, trial shows

A major trial found that avelumab, an immunotherapy drug, significantly improves long-term survival when given as maintenance treatment after chemotherapy for advanced bladder cancer. The two-year results are reshaping treatment standards for a disease that kills over 16,000 Americans annually, potentially expanding the addressable market for checkpoint inhibitors.

Originaltitel: Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up